According to data from the US Food and Drug Administration, there are about 6 cases of non-arteritic anterior ischemic optic neuropathy for every 100,000 people taking this type of drug every year. The FDA requires manufacturers of major GLP‑1 drugs such as Ozempic and Zepbound to add relevant warning labels; this eye condition can cause permanent vision loss. The FDA issued a safety notice on Monday stating that GLP-1 drugs may increase the risk of developing NAION, which can cause partial blindness. Patients have sued pharmaceutical companies, alleging that the drug caused their eyesight damage; major pharmaceutical companies such as Novo Nordisk and Eli Lilly are responding, indicating that current studies have not confirmed that GLP-1 drugs induce NAION. An Eli Lilly spokesperson said that patient safety is the company's primary consideration, is evaluating the FDA's latest requirements, and will respond soon. Novo Nordisk and Sanofi, which also have approved GLP‑1 products, have yet to comment.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.